Introduction：Basic information about CAS 395683-14-4|Imrecoxib, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Imrecoxib |
|---|
| CAS Number | 395683-14-4 | Molecular Weight | 369.477 |
|---|
| Density | 1.2±0.1 g/cm3 | Boiling Point | 604.1±55.0 °C at 760 mmHg |
|---|
| Molecular Formula | C21H23NO3S | Melting Point | / |
|---|
| MSDS | / | Flash Point | 319.1±31.5 °C |
|---|
Names
| Name | Imrecoxib |
|---|
| Synonym | More Synonyms |
|---|
Imrecoxib BiologicalActivity
| Description | Imrecoxib (BAP-909) is a novel and selective cyclooxygenase 2 (COX-2) inhibitor with an IC50 value of 18 nM, it also inhibits COX1- activity with an IC50 value of 115 nM. Imrecoxib (BAP-909) has anti-inflammatory effect[1]. |
|---|
| Related Catalog | Research Areas >>Inflammation/ImmunologySignaling Pathways >>Immunology/Inflammation >>COX |
|---|
| Target | Human COX-1:115 nM (IC50) Human COX-2:18 nM (IC50) |
|---|
| In Vitro | Imrecoxib (BAP-909) (0.1-10 µM; 24 hours) decreases COX-2 mRNA level induced by PMA+LPS at a dose dependent manner in U937 cells[1]. RT-PCR[1] Cell Line: U937 cells Concentration: 0.1 µM; 1 µM; 10 µM Incubation Time: 24 hours Result: Decreased COX-2 mRNA level. |
|---|
| In Vivo | Imrecoxib (BAP-909) (gastrointestinal administration; 5-20 mg/kg; 1 hour before carrageenan injection) inhibits carrageenan-induced acute inflammation, and the inhibitory effect is maximal at 4 hours[1]. Imrecoxib (BAP-909) (gastrointestinal administration; 5-20 mg/kg; started on day 7; 26 days) diminishes the secondary paw swelling and inhibits heat-inactivated BCG induced-inflammtory polyarthritis[1]. Animal Model: Rat carrageenan-induced edema model[1] Dosage: 5 mg/kg, 10 mg/kg, 20 mg/kg Administration: Gastrointestinal administration; 5-20 mg/kg; 1 hour before carrageenan injection Result: Inhibited the edema response with different doses. Animal Model: Rat adjuvant-induced arthritis (AIA) model[1] Dosage: 5 mg/kg, 10 mg/kg, 20 mg/kg Administration: Gastrointestinal administration; 5-20 mg/kg; started on day 7; 26 days Result: Inhibited adjuvant-induced chronic inflammation at the doses of 10 and 20 mg/kg. |
|---|
| References | [1]. Chen XH, et al. Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. Acta Pharmacol Sin. 2004 Jul;25(7):927-31. |
|---|
Chemical & Physical Properties
| Density | 1.2±0.1 g/cm3 |
|---|
| Boiling Point | 604.1±55.0 °C at 760 mmHg |
|---|
| Molecular Formula | C21H23NO3S |
|---|
| Molecular Weight | 369.477 |
|---|
| Flash Point | 319.1±31.5 °C |
|---|
| Exact Mass | 369.139862 |
|---|
| PSA | 62.83000 |
|---|
| LogP | 3.57 |
|---|
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
|---|
| Index of Refraction | 1.590 |
|---|
| InChIKey | AXMZZGKKZDJGAZ-UHFFFAOYSA-N |
|---|
| SMILES | CCCN1CC(c2ccc(S(C)(=O)=O)cc2)=C(c2ccc(C)cc2)C1=O |
|---|
Safety Information
Synonyms
| 3-(4-Methylphenyl)-4-[4-(methylsulfonyl)phenyl]-1-propyl-1,5-dihydro-2H-pyrrol-2-one |
| 4-(4-(methylsulfonyl)phenyl)-1-propyl-3-(p-tolyl)-1H-pyrrol-2(5H)-one |
| 2H-Pyrrol-2-one, 1,5-dihydro-3-(4-methylphenyl)-4-[4-(methylsulfonyl)phenyl]-1-propyl- |
| 2H-Pyrrol-2-one,1,5-dihydro-3-(4-methylphenyl)-4-[4-(methylsulfonyl)phenyl]-1-propyl- |
| 4-(4-(methylsulfonyl)phenyl)-1-propyl-3-(p-tolyl)-1,5-dihydro-2H-pyrrol-2-one |
